243 related articles for article (PubMed ID: 30504334)
1. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
Merrill SA; Brodsky RA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
[TBL] [Abstract][Full Text] [Related]
2. Complement in hemolytic anemia.
Brodsky RA
Blood; 2015 Nov; 126(22):2459-65. PubMed ID: 26582375
[TBL] [Abstract][Full Text] [Related]
3. Complement in hemolytic anemia.
Brodsky RA
Hematology Am Soc Hematol Educ Program; 2015; 2015():385-91. PubMed ID: 26637747
[TBL] [Abstract][Full Text] [Related]
4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
[TBL] [Abstract][Full Text] [Related]
6. Paroxysmal nocturnal haemoglobinuria.
Hill A; DeZern AE; Kinoshita T; Brodsky RA
Nat Rev Dis Primers; 2017 May; 3():17028. PubMed ID: 28516949
[TBL] [Abstract][Full Text] [Related]
7. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.
Singer AL; Locke JE; Stewart ZA; Lonze BE; Hamilton JP; Scudiere JR; Anders RA; Rother RP; Brodsky RA; Cameron AM
Liver Transpl; 2009 May; 15(5):540-3. PubMed ID: 19399743
[TBL] [Abstract][Full Text] [Related]
8. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
9. Paroxysmal nocturnal hemoglobinuria from bench to bedside.
Pu JJ; Brodsky RA
Clin Transl Sci; 2011 Jun; 4(3):219-24. PubMed ID: 21707954
[TBL] [Abstract][Full Text] [Related]
10. How I treat paroxysmal nocturnal hemoglobinuria.
Brodsky RA
Blood; 2021 Mar; 137(10):1304-1309. PubMed ID: 33512400
[TBL] [Abstract][Full Text] [Related]
11. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
[TBL] [Abstract][Full Text] [Related]
12. Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
Schmidt CQ; Smith RJH
Immunol Rev; 2023 Jan; 313(1):376-401. PubMed ID: 36398537
[TBL] [Abstract][Full Text] [Related]
13. Crovalimab: First Approval.
Dhillon S
Drugs; 2024 Jun; 84(6):707-716. PubMed ID: 38740735
[TBL] [Abstract][Full Text] [Related]
14. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Harder MJ; Kuhn N; Schrezenmeier H; Höchsmann B; von Zabern I; Weinstock C; Simmet T; Ricklin D; Lambris JD; Skerra A; Anliker M; Schmidt CQ
Blood; 2017 Feb; 129(8):970-980. PubMed ID: 28028023
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria.
Van Bijnen ST; Van Heerde WL; Muus P
J Thromb Haemost; 2012 Jan; 10(1):1-10. PubMed ID: 22077430
[TBL] [Abstract][Full Text] [Related]
16. How I treat paroxysmal nocturnal hemoglobinuria.
Brodsky RA
Blood; 2009 Jun; 113(26):6522-7. PubMed ID: 19372253
[TBL] [Abstract][Full Text] [Related]
17. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.
Risitano AM
Transl Med UniSa; 2014 Jan; 8():43-52. PubMed ID: 24778997
[TBL] [Abstract][Full Text] [Related]
18. Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs.
Bektas M; Copley-Merriman C; Khan S; Sarda SP; Shammo JM
J Manag Care Spec Pharm; 2020 Dec; 26(12-b Suppl):S14-S20. PubMed ID: 33356783
[TBL] [Abstract][Full Text] [Related]
19. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Gurnari C; Nautiyal I; Pagliuca S
Ther Clin Risk Manag; 2021; 17():1343-1351. PubMed ID: 34934322
[TBL] [Abstract][Full Text] [Related]
20. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
